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SUMMARY 
 
Protection against oxidative damage caused by excessive reactive oxygen species 
(ROS) by an antioxidant network is essential for the health of tissues, especially in the 
cardiovascular system. Here we identified a new gene with important antioxidant 
features by analyzing a null allele of zebrafish ubiad1, called barolo (bar). bar mutants 
show specific cardiovascular failure due to oxidative stress and ROS-mediated 
cellular damage. Human UBIAD1 is a non-mitochondrial prenyltransferase that 
synthesizes CoQ10 in the Golgi membrane compartment. Loss of UBIAD1 reduces 
the cytosolic pool of the antioxidant CoQ10 and leads to ROS-mediated lipid 
peroxidation in vascular cells. Surprisingly, inhibition of eNOS prevents Ubiad1-
dependent cardiovascular oxidative damage suggesting a crucial role for this enzyme 
and non-mitochondrial CoQ10 in NO signaling. These findings identify UBIAD1 as a 
new non-mitochondrial CoQ10-forming enzyme with specific cardiovascular 
protective function via the modulation of eNOS activity. 
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INTRODUCTION 
 
Reactive oxygen species (ROS) play an important role in signal transduction and 
physiological regulation of the cardiovascular system by facilitating various 
biological responses such as gene expression, cell proliferation and migration, 
apoptosis, and senescence in heart and endothelial cells (ECs) (Lander et al., 1996; 
Finkel et al., 2000, 2003; Hare et al., 2005; D'Autréaux and Toledano, 2007). In 
cardiovascular tissues ROS are normally produced in response to RTK and GPC 
receptors signaling, as well as during mechanical (shear) stress. Such oxidative 
species contribute to the regulation of cardiovascular homeostasis (Colavitti et al., 
2002; Werner, 2004; Ushio-Fukai, 2006). An antioxidant network is required to 
balance these ROS. This will prevent excessive oxidative damage which may 
contribute to different cardiovascular pathologies, including endothelial apoptosis and 
dysfunction, atherosclerosis, and also heart failure (Finkel, 2003; Giordano, 2005; 
Kuster et al., 2010). While several enzymes responsible for ROS production in ECs 
have been identified, many of the molecules involved in the endogenous antioxidant 
network are still unknown.  
A promising molecule known to play an important antioxidant role in the 
cardiovascular system is CoQ10 (also known as Coenzyme Q10 or ubiquinone) (Pepe 
et al., 2007; Kumar et al., 2009). CoQ10 is the only endogenously synthesized lipid-
soluble antioxidant (Crane, 2007; Bentinger et al., 2007). It is available in the 
membranes of the Golgi where it is present at an even higher concentration than in 
mitochondria, as well as in plasma membranes (Kalen et al., 1987; Crane, 2001; 
Bentinger et al., 2008). While the biosynthesis of CoQ10 in mitochondria has been 
studied in detail only a limited amount of data is available in regards to the synthesis 
of cellular membrane CoQ10. Interestingly, several in vivo experiments suggest that 
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CoQ10 synthesis may also occur in the Golgi and endoplasmic reticulum membranes. 
This synthesis provides the cellular membrane CoQ10 pool (Kalén et al., 1990). 
However, although hypothesized, a “non-mitochondrial” CoQ10 biosynthetic enzyme 
has not been identified as yet (Bentinger, et al., 2010). Identification of such an 
enzyme could be extremely useful to devise strategies to counteract the excess of 
ROS responsible for cellular oxidative damage (such as lipid peroxidation, protein 
nitrosylation and DNA oxidation) and therefore balance redox signaling especially in 
cardiovascular tissues.  
CoQ10 is a mobile lipophilic electron carrier which is critical for electron transfer 
both in the mitochondrial membrane for respiratory chain activity as well as in Golgi 
and plasma membranes for NAD(P)H-oxidoreductase-dependent reactions such as in 
NO synthesis (Navas et al., 2007). Endothelial nitric oxide synthase (eNOS) is a 
critical regulator of cardiovascular functions by generating nitric oxide (NO), which is 
an important mediator of cardiovascular homeostasis (Alp and Channon, 2004; 
Fostermann and Sessa, 2011). As in the case with non-mitochondrial CoQ10, eNOS is 
specifically localized in the Golgi and plasma membrane of heart and endothelial cells 
and it can be differentially regulated in these two cellular compartments (Fulton et al., 
2002). Interestingly, different reports over the years have suggested that CoQ10 may 
improve endothelial dysfunction by 'recoupling' eNOS and modulating NO-related 
signaling (Chew and Watts, 2004; Tsai et al., 2011).  
Here we identify UBIAD1 as an enzyme for CoQ10 synthesis at the level of Golgi 
membranes. By using a zebrafish null mutant for Ubiad1 and primary human cells 
silenced for UBIAD1, we show that UBIAD1 is a critical enzyme for oxidative stress 
protection. In particular UBIAD1 plays a strategic role by protecting cardiovascular 
tissues from eNOS-dependent oxidative stress. We propose a possible functional link 
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between UBIAD1, CoQ10 and NO signaling during cardiovascular development and 
homeostasis. 
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RESULTS 
Oxidative stress and cardiovascular failure characterize barolo mutants 
During two independent forward genetic screens for cardiovascular mutants 
(Tuebingen Screen, 2005; Jin et al., 2007), we identified mutations in the barolo (bar) 
gene (bart31131 and bars847). These mutations are recessive and show complete 
penetrance and expressivity. barolo mutants show distinct cranial vascular 
hemorrhages and pericardial edema in the context of wild-type body morphology 
(Figure 1A). To examine whether this phenotype is associated with cardiovascular 
defects, we crossed the mutations into Tg(kdrl:GFP)s843 (Figure 1B). Fluorescence 
microscopy analyses show that the hemorrhagic phenotype in bar mutants is 
accompanied by specific endothelial regression and fragmentation in the cranial and 
trunk vascular compartments (Figure 1C and 1D). Time-lapse analyses of trunk 
vasculature indicate that the bar phenotype starts around 36 hours post-fertilization 
(hpf)(Supplementary Movies 1-4) and that it is not due to general loss of blood flow. 
The cardiac edema of bar mutants is caused by a gradual breakdown of endocardial 
and myocardial cells in the heart leading to the collapse of the heart between 60 and 
72hpf (data not shown). All these features lead to the complete cardiac and vascular 
organ failure by 72hpf in bar mutant embryos. 
It has been demonstrated that cardiovascular failure is related to altered redox 
signaling and an increased production of reactive oxidative species (ROS)(Hare and 
Stamler, 2005). Intriguingly, bar mutants compared to wild-type siblings show altered 
redox balance and oxidative stress features evaluated as an increase of the 
NADP/NADPH ratio and as an overexpression of anti-oxidant genes, respectively 
(Figure 1E and 1F). Increase of ROS production occurs specifically in cardiovascular 
tissues as demonstrated by measuring oxidizing species in ECs of bar mutants using 
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the selective and stable ROS detector CellROX (Figure 1G). To better establish 
whether bar mutants are characterized by redox imbalance and oxidative stress we 
measured S-nitrosylation levels on heart and blood vessels sections of bar mutants. 
bar mutants show higher levels of S-nitrosylated proteins in heart and blood vessel 
cells as well as in pronephros as measured by an antibody against S-Nitroso-Cysteine 
(SNO-Cys) (Figure 1H). A high level of S-nitrosylated proteins is normally associated 
with altered redox signaling and cellular protection against oxidative stress (Stamler 
et al., 2001; Hess et al., 2005; Sun and Murphy, 2010). 
A particularly destructive aspect of oxidative stress is the production of ROS that, if 
not overcome by antioxidant mechanisms or compounds, cause extensive cellular 
DNA damage. We found that cardiovascular tissues from bar mutants are positive for 
8-hydroxy-2'-deoxyguanosine (8-OHdG), one of the predominant free radical-induced 
oxidative lesions in DNA (Figure 1I). Analyses of heart and blood vessel sections 
show that both myocardial and endothelial tissues of bar mutants exhibit ROS-
mediated DNA damage compared to controls.  
Since an unbalanced increase of ROS might lead to apoptosis and organ failure we 
evaluated whether oxidative stress in bar mutants ends up in causing cell death at 
later stages. Indeed, endothelial and endocardial cells in bar mutants were positive for 
TUNEL staining, and show typical morphological features of apoptotic cells at this 
stage (Figure 1L). In summary, both mutant embryos carrying the barolo mutation 
show increased oxidative stress that cause DNA damage and then cell death 
specifically in blood vessels and the heart.  
By positional cloning, we determined that bar encodes Ubiad1 (UbiA-domain 
containing protein 1)(Figure 1M). Sequence analyses show that the bart31131 mutant 
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allele contains a nonsense mutation (123 T>A) in ubiad1 introducing a premature stop 
codon at amino acid position 41, likely generating a null allele. The second allele of 
bar (bars847) bears a base change (185 T>A) leading to the substitution of a conserved 
leucine residue to glutamine at amino acid position 62 (Ubiad1L62Q)(Figure 1N). 
bars847 shows the same phenotypical features as bart31131 except for the fact that the 
phenotype is delayed by 12 hours (Figure S1A-E and S1T). Both bar allele mutants do 
not express Ubiad1 (Figure 1O) and are fully rescued by Ubiad1 mRNA expression. 
On the other hand, Ubiad1L62Q mRNA does not rescue the bart31131 mutant indicating 
that this amino acid mutation is sufficient to knock-out Ubiad1 activity (Figure 1P). 
To further test whether Ubiad1 regulates cardiovascular protection and survival, we 
knocked down Ubiad1 expression using an antisense morpholino oligonucleotide. 
Ubiad1 morphants show the same hemorrhagic phenotype and cardiovascular defects 
as bar mutants (Figure S1F-I).  
Analyses of ubiad1 mRNA expression in developing zebrafish embryos by RT-PCR 
and in situ hybridization reveal a ubiquitous expression at 24hpf in addition to a 
distinct expression in the heart at 48hpf (Figure S1J-L), in agreement with 
mammalian expression data (Nakagawa et al., 2010). In addition, cell transplantation 
and tissue-specific rescue experiments showed that Ubiad1 functions autonomously 
within endothelial and endocardial cells (Figure S1M-P and Supplementary Table). 
These data indicate that loss of ubiad1 triggers a progressive cardiovascular failure by 
increasing oxidative stress and apoptosis in heart and blood vessels suggesting a role 
for Ubiad1 as a controller of redox state and ROS levels in vertebrate cardiovascular 
tissues (Figure S1Q). Thereby, bar represents a unique model to study oxidative stress 
conditions and redox signaling during zebrafish development. 
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UBIAD1 is a new CoQ10 biosynthetic enzyme 
Bioinformatic analyses show that Ubiad1 is conserved amongst species and contains 
an UbiA prenyltransferase domain, present also in the vertebrate protein, Coq2. So 
far, the mitochondrial enzyme Coq2 is the only vertebrate enzyme known to 
synthesize CoQ10 through the prenylation of 4-hydroxybenzoic acid by oligoprenyl 
diphosphates (Forsgren et al., 2004). The CoQ10 molecule is composed of a redox 
active benzoquinone ring, which is connected to a polyisoprenoid side chain of 
variable length (typically 9/10-units in vertebrates)(Crane, 2001). As for Coq2, we 
speculate that Ubiad1 might catalyze the biosynthesis of CoQ10. To test our 
hypothesis we have measured CoQ10 levels in bar mutants and ubiad1 morphants by 
HPLC-MS technique (Figure 2A and 2B). The absence of Ubiad1 in zebrafish larvae 
significantly reduces CoQ10 levels (Figure 2C), while cholesterol levels are not 
significantly affected (Figure S2A). By time-course of synthesis analyses we found 
that CoQ10 increases during zebrafish embryonic development and is almost entirely 
produced by the zygote without any contribution from the yolk sac (Figure S2B). On 
the other hand, a significant amount of embryonic cholesterol is provided by the yolk 
sac throughout early development (Figure S2C). These data suggest that de novo 
zygotic synthesis of CoQ10 by Ubiad1 (and/or Coq2) is required for zebrafish 
development. 
To test whether it is the absence of CoQ10 synthesis in zebrafish embryos that causes 
the bar phenotype we injected CoQ10 in one-single cell stage bar mutants (Figure 
2D). Three different CoQ10 formulations significantly rescue bar mutants suggesting 
that the intake of CoQ10 in Ubiad1 deficient embryos may restore normal 
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cardiovascular development. A recent paper reports that UBIAD1 is required for 
Vitamin K2 production (Nakagawa et al., 2010). However, exogenous Vitamin K2 
injections did not rescue bar mutants (Figure 2D) and Vitamin K2 was undetectable in 
our experimental conditions (Figure S2D-K). Although it is possible that UBIAD1 
may catalyze several enzymatic activities, our data indicate that the lack of Vitamin 
K2 is not responsible for the cardiovascular phenotype in bar mutants.  
To provide biochemical evidence that Ubiad1 is able to synthesize CoQ10 we 
performed metabolic studies in zebrafish embryos by analyzing the ability of bar 
mutants to convert hydroxy-4-benzoic acid to CoQ10 (Figure 2E). We first confirmed 
that administration of 13C6-labelled hydroxy-4-benzoic acid (hydroxy-4-benzoic acid-
13C6) is metabolized to CoQ10-
13C6 in zebrafish embryos by injecting this C
13-labeled 
precursor in zebrafish embryos at one-cell stage. After 72hpf of incubation, lipids 
were extracted and analyzed by HPLC-MS to quantify the amount of CoQ10-13C6 
formed in this time frame (Figure 2E). As a matter of fact, bar mutants show a 
reduced CoQ10-13C6 production compared to wild-type siblings. Interestingly, we 
also detected a strong impairment of CoQ9-13C6 production (Figure 2F) indicating 
that zebrafish larvae can synthesize both CoQ9 and CoQ10 as can human cells 
(Turunen et al., 2004). In summary, Ubiad1 is a 4-OH-benzoic acid-prenyl-tranferase 
enzyme required for CoQ10 and CoQ9 biosynthesis in vivo. 
 
Ubiad1 and HMG-CoA reductase inhibitors act in the mevalonate pathway for 
CoQ10-dependent cardiovascular oxidative stress protection. 
The rate-limiting reaction in the biosynthesis of CoQ10 is the transfer of the 
polyprenyl-pyrophosphate (polyprenyl-PP) chain, derived from mevalonate, on to 4-
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OH-benzoic acid, derived from tyrosine metabolism (Bentinger et al., 2008)(Figure 
2A). We reduced the pool of polyprenyl-PP available for CoQ10 synthesis by treating 
zebrafish embryos with statins, inhibitors of its precursor (e.g. mevalonate)(Figure 
S3A). By blocking HMG-CoA reductase statins impair the mevalonate and FPP 
synthesis which is mandatory to synthetize the polyprenyl-PP chain (Figure 2A). 
Wild-type embryos (ubiad1+/+) treated with 100 or 500 nM of statin developed a bar-
like phenotype characterized by cranial hemorrhages, vascular regression and 
collapsed heart with high penetrance (Figure 3A-C). Statin treatments efficiently 
reduced CoQ10 synthesis without interfering with cholesterol levels probably due to 
the fact that statin treatment blocks de novo cholesterol biosynthesis, but does not 
interfere with the maternally-provided cholesterol (Figure 3D and 3E).  Wild-type 
zebrafish embryos treated at the same developmental stages with the squalene 
synthase inhibitor (SQI) or with farnesyl or geranyl-geranyl tranferase inhibitors (FTI 
or GGTI) did not exhibit a bar-like phenotype (Figure S3B) indicating that the 
absence of CoQ10 is the cause of the statin-induced cardiovascular oxidative 
phenotype. Furthermore, while treatment with concentration of 2.5 or 5 nM (low-
dose) of statin did not produce any phenotype in wild-type (ubiad1+/+) embryos, it 
caused hemorrhages, endothelial dysfunction, and altered heart morphology (e.g. bar-
like phenotype) in embryos heterozygous for ubiad1 (ubiad1+/-) (Figure 3F-I). The 
bar-like phenotype caused by statin treatments was efficiently rescued by exogenous 
administration of liposomal CoQ10 (Figure 3J and 3K and S3C). To address the role 
of the mevalonate pathway in protection from oxidative stress in vivo, we measured 
ROS levels in zebrafish embryos treated with HMG-CoA reductase inhibitors. A 
significant increase in ROS level is detected in statin-treated zebrafish embryos, and 
this oxidative stress was fully rescued by CoQ10 treatment (Figure 3L). These data 
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suggest that HMG-CoA reductase and Ubiad1 are on the same metabolic pathway to 
produce CoQ10 as a potent anti-oxidant molecule which protects cardiovascular 
tissues during development. Altogether, these findings lead us to propose UBIAD1 as 
an important target for therapeutic strategies involved in limiting side effects of statin 
treatments. 
 
UBIAD1 synthesizes CoQ10 in the Golgi compartment 
To verify whether Ubiad1 could be a new enzyme responsible for cellular CoQ10 
production, we examined its subcellular localization. Based on its amino-acid 
structure, Ubiad1 is well conserved among species and is predicted to be a 
transmembrane protein (Nickerson et al., 2010). Using human primary ECs we 
performed localization studies for endogenous UBIAD1. UBIAD1 localizes in an 
asymmetric perinuclear region that resembles the Golgi compartment (Figure S4A). 
Co-localization studies using the Golgi specific marker TGN46 demonstrate that 
endogenous UBIAD1 distributes in the proximity of the Golgi compartment (Figure 
4A). Also a GFP-tagged zebrafish Ubiad1 fusion protein when expressed in human 
ECs localizes in the same perinuclear region compartment and co-localize with the 
Golgi markers, GM-130 and -adaptin (Figure 4B and4C). To confirm that Ubiad1 is 
a Golgi protein, we treated Ubiad1-GFP-expressing cells with brefeldin A (BFA), an 
antibiotic that causes disassembly of the Golgi complex and accumulation of 
secretory proteins in the endoplasmic reticulum (Fujiwara et al., 1988). Under these 
conditions, we observe a rapid redistribution of Ubiad1-GFP proteins in cells treated 
with BFA thus supporting its Golgi localization (Figure 4D).  
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We then hypothesized that since UBIAD1 is localized in the Golgi compartment, this 
enzyme might be a non-mitochondrial CoQ10 prenyltransferase. To test this 
assumption we performed subcellular fractionation experiments on human ECs. Golgi 
membranes or mitochondria were isolated and analyzed for UBIAD1 expression. 
Corroborating our previous immunofluorescence analyses, we detected UBIAD1 only 
in Golgi compartments and not in mitochondria (Figure 4E). We then analyzed de 
novo CoQ10 synthesis in these subcellular fractions by incubating ECs with the 
hydroxy-4-benzoic acid-13C6 precursor. These experiments show a significant 
decrease in CoQ10-13C6 production in Golgi compartments compared to 
mitochondrial fractions when UBIAD1 expression is reduced (Figure 4F). These data 
strongly indicate that UBIAD1 is a new CoQ10 biosynthetic enzyme located in the 
Golgi membrane compartment where large amounts of cellular CoQ10 are normally 
synthesized (Kalén et al., 1990; Swiezewska et al., 1993).   
 
SCCD mutations protect cardiovascular tissues from oxidative stress by CoQ10 
production 
Mutations in the UBIAD1 gene are linked to the autosomal dominant eye disease 
Schnyder Crystalline Corneal Syndrome (SCCD; OMIM 121800)(Weiss et al., 2007; 
Orr et al., 2007; Yellore et al., 2007; Weiss et al., 2008). By genetic analyses, two of 
the most common UBIAD1 mutations found in SCCD patients lead to the N102S and 
D112G substitutions. A major unresolved issue is whether these mutations affect the 
activity of the UBIAD1 protein. We generated human UBIAD1 constructs carrying 
these mutations (UBIAD1-N102S and UBIAD1-D112G) and performed rescue 
experiments in the bar mutants to test their effect on UBIAD1 function (Figure 5A). 
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The SCCD variants were able to rescue the loss of Ubiad1 during zebrafish 
development indicating that these variants are biologically active. We then tested 
these variants for levels of expression and CoQ10 synthesis in human EC. Compared 
to wild-type UBIAD1 protein, SCCD variants were expressed at higher levels (Figure 
5B). Furthermore, human ECs expressing the UBIAD-SCCD mutant proteins 
produced higher CoQ10 levels compared to wild-type protein (Figure 6C and D). 
Intriguingly, SCCD mutations did not affect cholesterol synthesis in human ECs 
(Figure 5E). These findings suggest that the SCCD variants are effective in CoQ10 
production in tranfected cells. Altough it remains unclear why SCCD mutation would 
results in the SCCD phenotype these results do suggest a reassessment of the 
pathological features of SCCD patients. 
 
Ubiad1 and Coq2 play different roles in CoQ10-mediated cardiovascular 
oxidative protection. 
CoQ10 is a mobile lipophilic electron carrier critical for electron transfer by the 
mitochondrial inner membrane respiratory chain (Mitchell, 1961; Turunen et al., 
2004; Duncan et al., 2009). Primary deficiency of CoQ10 (OMIM 607426) is 
characterized in humans by five major clinical phenotypes: 1) an encephalomyopathic 
form with seizures and ataxia; 2) a multisystem infantile form with encephalopathy, 
cardiomyopathy and renal failure; 3) cerebellar ataxia with marked cerebellar atrophy; 
4) Leigh syndrome with growth retardation and 5) pure myopathy. Primary CoQ10 
deficiencies have been associated with mutations in mitochondrial CoQ10 
biosynthetic genes, such as COQ2 (Salviati et al., 2005; Quinzii et al., 2006). 
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In order to investigate whether the Golgi-localized Ubiad1 and the mitochondrial-
localized Coq2 can have different functions in living organisms, we knocked-down 
Coq2 expression during zebrafish development by morpholino (MO) injections. 
Similar to Drosophila sbo/coq2 mutants (Liu et al., 2011), coq2 morphants are 
characterized by a general developmental delay, small body and severe hindbrain 
edema (Figure S5A-C). Interestingly, coq2 morphants display a short but normal 
swimming behavior, indicating that muscles are unlikely to be directly affected but 
that the energy is possibly inadequate for normal swimming (data not shown). These 
phenotypes do not occur in bar mutants or ubiad1 morphants, and, although a strong 
increase in oxidative stress occurs in coq2 morphants (Figure 6B), they did not show 
blood vessel regression (Figure 6A). These data indicate that loss of Coq2 leads to 
oxidative stress but it does not significantly affect vascular integrity and survival. We 
measured CoQ9 and CoQ10 levels, and as expected, they dropped in coq2 and ubiad1 
morphants compared to controls and even more in double morphants (Figure 6C and 
S5D). Loss of Ubiad1 and Coq2 in vivo unequivocally causes a decrease in CoQ10 
levels which possibly increases oxidative damage in different subcellular 
compartments leading to different embryonic phenotypes. 
To test whether Coq2 might compensate for loss of Ubiad1 we performed rescue 
experiments by injecting mRNA encoding for Coq2 in bar mutants (Figure 6D). 
While coq2 mRNA injection could rescue coq2 morphants (data not shown) it did not 
rescue bar mutants suggesting that Coq2 does not protect cardiovascular tissues from 
oxidative stress during zebrafish development. MitoQ is a mitochondria-targeted 
antioxidant (Murphy and Smith, 2007). Due to its selective accumulation within 
mitochondria, MitoQ only protects against the mitochondrial oxidative damage that is 
caused in embryos and cells by blocking mitochondrial CoQ10 synthesis through 
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knocking down Coq2 (Figure S5E). However, MitoQ (which will not interact with the 
Golgi apparatus) did not rescue bar mutants (Figure 6D) indicating that the two 
different subcellular pools of CoQ10 contribute in quite distinct ways to the 
phenotype of living organisms.  
To demonstrate the existence of a functional difference between the subcellular pools 
of CoQ10, we used human primary ECs in which we could silence to the same extent 
UBIAD1 and COQ2 genes. The silencing of these two genes causes an increase in 
oxidative stress and accumulation of oxidative damage (Figure 6E). We then 
compared the effects of these two genes on CoQ10 production, mitochondrial 
viability and oxidative degradation of cellular lipids. Initially we analyzed the 
efficiency of UBIAD1 and COQ2 in total CoQ10 biosynthesis by performing labeled 
precursor experiments where 4-hydroxybenzoic acid-13C6 was added to human ECs 
previously transfected with siRNA for UBIAD1 (siUBIAD1) or for COQ2 (siCOQ2) 
or both. Lipids were extracted and analyzed by HPLC-MS to quantify the amount of 
CoQ10-13C6 formed (Figure S5F). Silencing of UBIAD1 or COQ2 individually or 
together significantly reduced CoQ10-13C6 production. We also confirmed the 
efficiency of UBIAD1 and COQ2 siRNAs in decreasing endogenous total CoQ10 
levels in ECs (Figure 6F). Interestingly the silencing of the UBIAD1 gene did not 
significantly interfere with the transcriptional regulation of COQ2 and vice versa, 
indicating that the effect on CoQ10 levels from the silencing of one gene could not be 
altered by upregulation of the other (Figure 6G). 
To further evaluate the function of UBIAD1, we analyzed mitochondrial morphology 
and viability in ECs that have been silenced for UBIAD1 or COQ2. The absence of 
COQ2 significantly altered mitochondrial morphology (Figure S5G and S5H) and 
mitochondrial membrane potential (Figure 6H) which can indeed be rescued by 
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MitoQ (Figure S5I). Mitochondrial damage could not be detected in UBIAD1-
silenced cells indicating that the lack of the mitochondrial pool of CoQ10 in COQ2-
silenced cells exclusively impaired mitochondrial function. 
High levels of CoQ10 have been found in cellular membranes, including the Golgi 
and plasma membranes (Kalen et al., 1987; Turunen et al., 2004). The presence of 
CoQ10 in non-mitochondrial membranes have been associated with its role in 
protecting membrane lipids from peroxidation as well as from an extracellular-
induced ceramide-dependent apoptotic pathway (Navas et al., 2007). Since UBIAD1 
is specifically localized in Golgi membrane and Ubiad1 null mutants die by apoptosis 
we hypothesize a specific role for this enzyme in membrane protection from oxidative 
damage. When we first evaluated oxidative degradation of lipids by measuring lipid 
peroxidation in siUBIAD1-treated cells (Figure 6I). ECs without a cellular membrane 
pool of CoQ10 showed twice the level of oxidized fatty acid lipids indicating a 
functional role for UBIAD1 in protection from oxidative species specifically localized 
in cellular but not mitochondrial membrane. We conclude that UBIAD1-derived 
CoQ10 prevents lipid peroxidation either directly or through the regeneration of other 
antioxidants such as Vitamin E.  
In summary, we have demonstrated that in endothelial cells (and possibly all 
cardiovascular tissues) both UBIAD1 and COQ2 are CoQ10 biosynthetic enzymes. 
Their different subcellular localization drives distinctive functions inside the cells: the 
UBIAD1-synthetized CoQ10 works mainly as antioxidant for cellular membranes, 
while the COQ2-synthesized CoQ10 controls mitochondrial function. 
 
UBIAD1 prevents a shear stress/Klf2a/eNOS-mediated oxidative stress pathway 
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A hemodynamic environment, such as shear stress, is known to lead to ROS 
generation which is responsible for vascular remodeling and angiogenesis (Ungvari et 
al., 2006; Matlung et al., 2009). Several studies have shown that Kruppel-like factor 2 
(Klf2) is an immediate mediator of hemodynamic forces created by blood flow. Klf2 
regulates flow-dependent blood vessel integrity both in zebrafish and mice (Lee et al., 
2006; Nicoli et al., 2010). We tested if a shear stress-Klf2a pathway can modulate the 
bar phenotype and oxidative stress signaling by injecting cardiac troponin T2 (tnnt2) 
morpholino to block blood circulation (Sehnert et al., 2002) and klf2a morpholino 
(Nicoli et al., 2010) in bar mutants. In both cases we detected a significant delay of 
the bar phenotype as assessed by intersegmental vessels (Se) disintegration (Figure 
S6A and S6B). klf2a morpholino injection in barolo mutants lead to a partial recovery 
of oxidative stress in ECs (Figure S6C). These data indicate that a Klf2a-dependent 
shear stress pathway is required for oxidative stress conditions in bar mutants and that 
loss of Ubiad1 in vivo can be protected by impairment of this pathway.  
In human endothelial cells KLF2 has been found to be directly responsible for 
endothelail nitric oxide synthase (eNOS) expression and signaling (Searles, 2006). 
Recently, a blood flow-dependent klf2a-NO signaling cascade has been identified in 
developing zebrafish embryos to be required for stabilization of the hematopoietic 
stem cell (HSC) program (Wang et al., 2011). We have investigated the role of eNOS 
in bar mutants. Endothelial nos isoforms have been well characterized in zebrafish 
development (Fritsche et al., 2000; Pelster et al., 2005; North et al., 2009; Wang et al., 
2011). We performed knock-down experiments of nos1 (the zebrafish orthologue of 
mammalian endothelial Nos) in bar mutants. Inhibition of nos1 expression 
significantly rescued the bar mutant phenotype as well as endothelial regression 
(Figure 7A and 7B). Because abrogation of nos1 expression may interfere with HSC 
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development and blood flow we treated bar mutants at the onset of oxidative stress 
(32hpf) with the selective inhibitor of eNOS activity, N-nitro-L-arginine methyl ester 
(L-NAME)(North et al., 2009). L-NAME treatment promoted a full morphological 
and functional cardiovascular recovery of a statistically significant number of bar 
mutants (Figure 7C and 7D and S6E). This recovery was carefully evaluated for ROS 
level and altered redox signaling (SNO-Cys staining) in ECs. Blocking of eNOS 
activity by L-NAME treatment significantly reduced oxidative stress in endothelial 
cells of bar embryos (Figure 7E) and restored normal redox signaling (Figure 7F and 
S6E). Interestingly, pronephric duct cells affected by oxidative stress in bar mutants 
did not improve after L-NAME treatments (Figure S6F). To test whether the source of 
ROS in the absence of UBIAD1 was caused by eNOS, we silenced eNOS in primary 
human endothelial cells. ROS levels could be fully normalized by reducing eNOS 
expression in siUBIAD1-treated cells (Figure 7G).  
To further define the role of NO signaling in causing the bar mutant phenotype, we 
evaluated the effect of the NO donor S-nitroso-N-acetyl-penicillamine (SNAP) on bar 
mutants. SNAP treatments did aggravate the bar phenotype by increasing oxidative 
species in these mutant embryos (Figure S6D-F).  
Altogether these data indicate that eNOS may be responsible for ROS accumulation 
in bar mutants. It has been demonstrated that when eNOS is in a “coupled” 
conformation it produces NO, but when essential cofactors are limited, superoxide 
(O2˙) is produced by eNOS instead of NO (a so-called “uncoupled” 
conformation)(Fostermann and Sessa, 2011): as a consequence eNOS no longer 
produces NO but instead generates superoxide and causes oxidative stress in 
cardiovascular tissues. To verify whether the NO-forming activity of eNOS was 
compromised due to the lack of Ubiad1 and Golgi-CoQ10, we measured NOS activity 
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in bar mutants and human ECs silenced for UBIAD1. The lack of Ubiad1 drastically 
reduced the formation of NO in zebrafish embryos (Figure S6H) as well as in human 
ECs (Figure 7H).   
We measured tissue specific NO levels in bar mutants by imaging DAF-2DA staining 
in live embryos. NO accumulation was reduced in the notochord (NC) and was 
completely absent in the bulbus arteriosus (BuA) of bar mutants compared with 
controls (Figure S6I). All together we show a specific role for Ubiad1 on regulation of 
eNOS-mediated NO formation in endothelial and cardiovascular cells in vivo. 
These data indicate that the primary source of ROS causing cardiovascular oxidative 
stress in bar mutant as well as in ECs lacking UBIAD1 is dependent on eNOS 
activity. Therefore, we propose an unexpected functional link in the Golgi 
compartments between UBIAD1 and COQ10 in regulating eNOS activity and 
eventually NO signaling during cardiovascular development and homeostasis.  
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DISCUSSION 
Ubiad1 is a prenyltranferase enzyme required for CoQ10 biosynthesis in Golgi 
membranes. 
CoQ10 is an important cellular and mitochondrial redox component and the only 
endogenously produced lipid-soluble antioxidant (Bentinger et al., 2010). Although 
the genes encoding for the CoQ10 biosynthetic enzymes have been identified in 
bacteria and yeast, there is still only limited information about these synthetic 
enzymes in vertebrates (Turunen et al., 2004). The rate-limiting enzyme for the 
biosynthesis of CoQ10 is the enzyme that catalyzes the condensation of the 
polyisoprenoid chain with the benzoquinone ring. So far, the mitochondrial COQ2 
enzyme has been considered the only prenyltransferase able to catalyze this reaction 
(Trevisson et al., 2011). Here we identified UBIAD1 as a novel vertebrate CoQ10 
prenyltransferase. UBIAD1 contains an UbiA prenyltransferase domain also present 
in vertebrate COQ2. While COQ2 encodes a mitochondrial prenyltransferase, we 
found that UBIAD1 resides in the Golgi compartment where it produces CoQ10. 
While the presence of CoQ10 in non-mitochondrial membranes was previously 
explained by the existence of specific mechanisms for its redistribution within the cell 
(Crane and Morre, 1977; Jonassen and Clarke, 2000), our data now formally 
demonstrate that CoQ10 are synthetized in the Golgi compartment.  
In favour of our hypothesis of a Golgi-synthetized CoQ10 it has been recently 
reported that COQ6, COQ7, and COQ9 which are critical enzymes for CoQ10 
maturation are also localized in the Golgi compartment (Heeringa et al., 2011). 
Similarly, these authors suggested that the Golgi-localized pool of CoQ10 may 
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function in specific cells as an essential antioxidant for plasma membrane lipids that 
are normally derived from the Golgi compartment.  
In this work we demonstrated that the existence of two distinctive ubiquinone 
prenyltransferases act to resolve different molecular functions inside the cells and in 
living organisms. We found that COQ2-mediated CoQ10 production is mainly for 
mitochondrial respiratory chain function and energy production, while UBIAD1-
mediated CoQ10 production is important for membrane redox signaling and 
protection from lipid peroxidation. These results are in agreement with the different 
subcellular compartmentalization of these two enzymes. 
 
Ubiad1 and CoQ10: an anti-oxidant system controlling redox cellular (plasma) 
membrane in cardiovascular tissues. 
Oxidative damage is caused by an imbalance between the production of ROS and the 
antioxidant network, in favor of the former. Although ROS are predominantly 
implicated in causing cell damage and premature aging via oxidation of DNA, lipids 
and proteins, they also play a major physiological role in several aspects of 
intracellular signaling and regulation especially in cardiovascular tissues (Hare and 
Stamler, 2005; Kuster et al., 2010). Therefore, heart, endothelial and vascular smooth 
muscle cells need an efficient anti-oxidant network to balance ROS levels. We have 
shown a set of genetic and cellular data that reveal an unexpected role for UBIAD1 as 
an essential antioxidant gene with important functions in the protection of heart and 
endothelial cells from oxidative stress at the level of cellular membranes by producing 
CoQ10 in the Golgi for distribution to non-mitochondrial membranes throughout the 
cell. In addition to its crucial role in oxidative phosphorylation, CoQ10 plays another 
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vital role in cellular function as an antioxidant molecule. The antioxidant nature of 
CoQ10 is derived from its function as an electron carrier: in this role, CoQ10 
continually shuttles between oxidised and reduced forms. As it accepts electrons, it 
becomes reduced. As it gives up electrons, it becomes oxidized. In its reduced 
ubiquinol form, the CoQ10 molecule will quite easily give up one electron and, thus, 
act as an antioxidant. In such a way, CoQ10 inhibits lipid peroxidation by acting as a 
chain breaking antioxidant. Moreover, CoQH2 reduces the initial lipid peroxyl radical, 
with concomitant formation of ubisemiquinone and an alkyl peroxide. This quenching 
of the initiating peroxyl radicals thereby prevents the propagation of lipid 
peroxidation and protects not only lipids, but also proteins from oxidation. In 
addition, the reduced form of CoQ10 might also contribute to the stabilization of the 
plasma membrane, regenerating antioxidants such as α-tocopherol. A crucial role in 
all these processes is played by NAD(P)H-dependent reductase(s) acting at the plasma 
membrane to regenerate the reduced ubiquinol form of CoQ10, contributing to the 
maintainance of its antioxidant properties (Navas et al., 2007). This finding also opens 
a new and interesting link among cellular redox-state and metabolic pathways such as 
the mevalonate pathway. 
 
An essential function for Ubiad1/CoQ10 in regulation of NO signaling 
Here we have demonstrated that UBIAD1 protects cardiovascular tissue from ROS-
mediated oxidative stress by producing CoQ10 located in Golgi and plasma 
membranes. Major enzymatic pathways responsible for the generation of ROS in 
cardiovascular tissues are mainly NADPH oxidases and eNOS (Browning et al., 
2012). By using drug inhibition and gene inactivation approaches we identify eNOS 
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dysfunction as the primary cause of ROS increase in bar mutant and UBIAD1-
silenced human ECs. The NO synthetized by eNOS is an essential factor for 
cardiovascular development and homeostasis in vertebrates (Alp and Channon, 2004; 
Pelster et al., 2005; North et al., 2009; Wang et al., 2011). It has been suggested that 
CoQ10 might have a positive role in modulating NO-related pathways by recoupling 
eNOS in endothelial cells (Stuehr et al., 2001; Chew and Watts, 2004; Tsai et al., 
2011). eNOS is a “L-arginine, NADPH:oxygen oxidoreductases, NO forming 
enzyme” (EC 1.14.13.39) that coupled reduction of molecular oxygen to L-arginine 
oxidation and generation of L-citrulline and NO. eNOS controls the flow of electrons 
donated by NADPH to flavins FAD and FMN in the reductase domain of one 
monomer through BH4 to the ferrous–dioxygen complex (Fe) in the oxygenase 
domain. When NADPH and BH4 cofactors are limiting, electron transfer becomes 
uncoupled from L-arginine oxidation, the ferrous–dioxygen complex dissociates, and 
superoxide (O2
− •) is generated from the oxygenase domain (Schmidt and Alp, 2007). 
Our data indicate that barolo mutants lacking the Golgi pool of CoQ10 die due to the 
accumulation of oxidative damage in cardiovascular tissues caused by ROS produced 
by eNOS. Here, we suggest a speculative mechanism whereby UBIAD1 is required in 
the Golgi compartment to produce CoQ10 as an important cofactor for eNOS-
mediated NO production (Figure 7I). Such a model could fit with the oxido-reductive 
properties of CoQ10 and eNOS: the electron flux inside eNOS that is mandatory to 
produce NO from L-arginine might require, together with NADPH and BH4, also 
CoQ10. Such function would not be very different from what CoQ10 does in the 
mitochondrial electron transport chain (ETC) coupling electron transfer between an 
electron donor (such as NADH) and an electron acceptor (such as O2) with the 
transfer of H+ ions across the mitochondrial inner membrane. In the Golgi membranes 
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the flow of electrons within eNOS transfers electrons from NADPH to the flavins 
FAD and FMN, which have the capacity to reduce molecular oxygen. If the ETC is 
disturbed, such as in the absence of UBIAD1/CoQ10, the ferrous-dioxygen complex 
dissociates, and O-2 is generated from the FMN oxygenase domain (Liu et al., 2002; 
Rigoulet et al., 2011). In cardiovascular tissues the CoQ10 produced by UBIAD1 in 
the Golgi compartment may be an important cofactor to maintain eNOS in a coupled 
conformation (e.g. required to produce physiological NO) and, eventually, quench 
leaking-uncoupled electrons. We speculate that when UBIAD1/CoQ10 in the Golgi 
compartment is absent or decreased (bar mutants and siUBIAD1-treated cells) eNOS 
switches to an “uncoupled” conformation producing oxidative species instead of NO 
and causing cardiovascular oxidative damage (Figure 7I). Further experiments need to 
be done to assess this hypothesis as well as the possibility that other NOS (e.g. nNOS) 
could be affected by the lack of Ubiad1 in vivo. 
In summary, our study places UBIAD1 in a new pathway with important therapeutic 
implications for cardiovascular failure, such as the opportunity to decrease oxidative 
damage and counteract some of the side effects of statins. In addition, 
pharmacological or genetic stimulation of UBIAD1, as a new CoQ10 biosynthetic 
enzyme, represents a new promising therapeutic approach for anti-oxidant-related 
diseases such as aging and cancer.  
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EXPERIMENTAL PROCEDURES  
 
Zebrafish strains, mapping, genotyping  
Embryos and adult fishes were raised and maintained under standard laboratory 
conditions. bars847 and bart31131 mutants were generated by ENU mutagenesis as 
previously described (Jin et al., 2007).  
Oxidative stress analyses in zebrafish embryos and cells 
Oxidative damage was detected by immunofluorescence on agarose sections of 
zebrafish embryos with following markers: anti-8-hydroxy-2'-deoxyguanosine (1:500, 
Abcam) and anti-S-Nitroso-cysteine (1:250, Sigma).  
ROS levels were quantitated in isolated human (HUAEC) and zebrafish 
(Tg(Kdrl:GFP)s843 ) endothelial cells with CellROX Deep Red Reagent (Invitrogen; 
2,5μM) and analyzed by FACS.  
Western blot analyses 
Western blot analyses were performed with following primary antibodies: mouse anti-
UBIAD1 (9D4; 1:500), goat anti TERE1 (UBIAD1)-N16 (1:250; SantaCruz), mouse 
 BD Biosciences), rabbit anti 
HADHA (Hydroxyacyl-CoA Dehydrogenase/3-ketoacyl-CoA thiolase/enoyl-CoA 
Hydratase (trifunctional protein), Alpha subunit)(1:5000; Abcam). 
Generation of human SCCD mutation in UBIAD1 
Constructs containing the SCCD mutation N102S and D112G were introduced in 
pCS2+ plasmids and used for expression in zebrafish embryos as well as human ECs. 
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NO levels and NOS activity in zebrafish embryos and human ECs 
NOS activity was assayed using the NOS Activity Assay Kit (Cayman Chemicals). 
NO levels were detected using the DAF-2 DA (Calbiochem).  
Cell culture experiments 
Human primary EC were purchased from Lonza and cultured according to the 
manufacturer’s protocols (Lonza). Cells were electroporated with siRNA 
(Dharmacon). Detailed protocols are available on Supplemental Experimental 
Procedures.  
HPLC analyses 
Samples for HPLC-MS analysis were zebrafish embryos (n=25) or human HUAEC 
(2×106 cells). CoQ10 and CoQ9 levels were detected by HPLC-MS or HPLC-UV (as 
indicated). Total cholesterol from zebrafish embryos was analyzed by HPLC-UV. 
Vitamin K2 from zebrafish embryos and cell lysates was analyzed by HPLC-MS/MS. 
Metabolomics experiments were carried on ECs and zebrafish embryos from bart31131 
and bars847 heterozygote intercrosses. 4-Hydroxy-benzoic acid-13C6 (Euriso-Top) was 
stocked in DMSO and dissolved in cell culture medium (1mM) or microinjected in 
zebrafish embryo at one cell stage ( 2mM). ECs or embryos were extracted after 48 or 
72 hours, respectively, after labeled precursor administration. Extracts were quantified 
by HPLC-MS for following molecules: CoQ10, CoQ9, and CoQ9-13C6 , CoQ10-
13C6 . 
For detailed procedure of sample extraction and analysis refer to Supplemental 
Experimental Procedures.  
Exogenous CoQ10 and Vitamin K administration 
All chemicals and solvents for liposomal CoQ10 and Vitamin K formulation were 
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purchased from Sigma Aldrich and Avanti Polar Lipids. Liposomal SINAMIT® was 
a gift from Dr. Franz Enzmann (MSE Pharmazeutika GmbHT), liposomal LiQsorb® 
was from Tishcon Corp. MitoQ was synthetized as previously reported (Murphy and 
Smith, 2007). All CoQ10 and vitamin K formulations were tested for toxicity and 
microinjected at specific concentrations into zebrafish embryos at one cell stage.  
See Supplemental Data for more details and all other experimental procedures.
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FIGURE LEGENDS 
 
Figure 1: Loss of Ubiad1 induces cardiovascular failure in zebrafish embryos by 
increasing oxidative stress.  
(A-B) Siblings (sib) and barolo t31131 (bar) mutant embryos at 65 hpf. (A) Vascular 
hemorrhages (asterisks) and heart failure (arrowhead) in bar. (B) Tg(kdrl:GFP)s843 
bar show vascular integrity defects (arrows) and collapsed endocardium (arrowhead). 
Scale bar, 300m. (C) Tg(Fli1a:GFP)y1 bar show severe loss of cranial network 
vasculature and fragmented endothelium (arrow) at 65hpf. (D) Confocal images of 
trunk vasculature of Tg(kdrl:GFP)s843 bar report loss of ECs at the level of Se, DA 
(arrows) and PCV. Scale bar, 50m. (E) NADP+/NADPH ratio at 60hpf. Increased 
ratio is indicative of oxidative stress state. (F) Real-time PCR analysis show up 
regulation of the antioxidant genes glutathione peroxidase1a (gpx1a) and heme-
oxigenase1 (hmox1) in bar at 56hpf. Data are means ± SD. (G) Quantification of 
oxidative stress level in ECs derived from Tg(kdrl:GFP)s843 embryos at 56hpf. (H) 
Immunofluorescence analyses for S-Nitroso-Cysteine (SNO-Cys, red) and DNA(blue) 
in Tg(kdrl:GFP)s843 bar  and sib embryos at 60hpf. Upper left: heart transverse 
sections; upper right: quantification of SNO-Cys positive cells. Lower left: trunk 
vasculature transverse sections; lower right: quantification of SNO-Cys positive cells. 
Scale bar, 75 m. Specific SNO-Cys signals were also detectable in pronephros and 
myocardium of bar (arrowhead). (I) Immunofluorescence analyses for 8-hydroxy-
2'deoxyguanosine (8OHdG, red) and DNA (blue) in Tg(kdrl:GFP)s843bar  and sib at 
56 hpf. Upper left: heart transverse sections; upper right: quantification of 8OHdG 
positive cells. Scale bars, 50 m. Lower left: trunk vasculature transverse sections; 
lower right; quantification of 8OHdG positive. Scale bar, 20m. bar show specific 
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8OHdG staining in endocardial and endothelial cells (arrows) and myocardium 
(arrowhead). (L) TUNEL-positive (red) cells show apoptosis in endocardium and 
endothelium (arrows). Upper left: heart transverse sections of Tg(kdrl:GFP)s843 bar 
s847 and sib ; upper right: quantification of TUNEL-positive cells. Lower left: 
transverse sections of trunk vasculature; lower right: quantification of positive cells in 
DA and PCV. Scale bars, 20 µm. (M) Genetic map of the zebrafish barolo locus. The 
SSLP markers (z22307) was used to identify the “zero recombinant” region by 
analysis of 987 diploid mutants. (N) Schematic representation of zebrafish Ubiad1. 
UbiA: UbiA domain. (O) Western blot analysis of protein extracts from bars847 and 
bart31131 and respective siblings at 72hpf. (P) Embryos from bars847 and bart31131 
heterozygote intercrosses were injected with mRNA encoding for wild-type ubiad1 
mRNA, ubiad1L62Q or fluorescent protein cherry (ctrl). bars847 as well as bart31131 were 
not rescued by microinjection of ubiad1L62Q  mRNA.  
A, atrium; V, ventricle; DA, dorsal aorta; PCV, posterior cardinal vein; BuA bulbus 
arteriosus; PD, pronephric ducts; E, endocardium; M myocardium. All data are means 
± SEM **p<0.01, ***p<0.001.  
See also Figure S1. 
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Figure 2: Ubiad1 is a new prenyltranferase required for CoQ10 biosynthesis in 
vertebrates. 
(A) Schematic representation of the 13C-based metabolomic approach used to 
demonstrate that Ubiad1 is a 4-OH-benzoic acid-prenyl tranferase enzyme. Coenzyme 
Q10 (CoQ10) biosynthesis starts with formation of a hydroxy-benzoic acid head 
group (4-OH-benzoic acid) and a lipophilic polyisoprenoid tail (polyprenyl-PP). The 
aromatic precursor of the benzoquinone ring (4-OH-benzoic acid) derives from 
tyrosine, an essential amino acid in vertebrates. Synthesis of the polyisoprenoid tail 
takes place in the cytoplasm starting from acetyl-CoA through the mevalonate 
pathway (which is shared in common with the cholesterol and dolichol biosynthetic 
pathways). The polyisoprenoid tail is assembled by polyprenyl diphosphate synthase, 
which is responsible for determining the number of isoprene units (designated as n). 
Next critical step is the condensation of the polyisoprenoid chain with the 
benzoquinone ring to form the 4-hydroxy-3-polyprenyl benzoic acid intermediate 
(PPHB) by a 4-OH-benzoic-polyprenyl-tranferase (UbiA-containing enzyme). The 
subsequent reactions (O-methylations and C-methylations, hydroxylations and 
decarboxylations) modify the structure of the aromatic ring, but some of the enzymes 
involved are still unknown. Exogenous 4-OH-benzoic acid-13C6 containing heavy 
carbon element (13C) is administered to embryos and cells so that de novo synthesis of 
PPHB and therefore CoQ10 can be monitored by HPLC-MS analyses. Loss of UbiA-
containing enzymes (red) blocks the condensation of the polyisoprenoid chain with 
the benzoquinone ring and then formation of CoQ-13C6. 
13C6-labeled compounds used 
or detected in this work are shown in green. (B) High resolution MS spectrum of lipid 
extracts from wild-type zebrafish embryos. The MS spectrum of the HPLC fraction 
containing CoQ10 reveals the analyte as [CoQ10-Na+] at m/z = 885.6751. 
41 
 
 
 
(C) HPLC-MS analyses show that bar mutants  are characterized by a reduced level 
of endogenous CoQ10 in comparison to their siblings. (D) Exogenous supplement of 
CoQ10, but not of VitaminK2, can efficiently rescue bar mutants. CoQ10F1; 
liposomal CoQ10 preparation 0,6 mM; CoQ10F2, LiQsorb® Liposomal CoQ10 Gel 
0,6 mM; COQ10 F3, SANOMIT® nano-particles CoQ10 liquid, 6,9 mM;  VitK ; 
Liposomal Vitamin K2 0,3 mM. (E-F) Levels of 13C6-labeled CoQ10 (CoQ10-
13C6) 
and 13C6-labeled CoQ9 (CoQ9-
13C6) are detected by HPLC-MS in bar mutants and 
siblings at 72hpf. Loss of Ubiad1 expression protein significantly reduces de novo 
CoQ10-13C6 synthesis by 78% (E) and de novo CoQ9-
13C6 synthesis by 66,5% (F). 
All data are means ± SEM **p<0.01,***p<0.001.  
See also Figure S2. 
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Figure 3: Block of mevalonate pathway causes cardiovascular failure in zebrafish 
embryos by reducing CoQ10 synthesis. 
(A) wild-type (wt) embryos at 72hpf treated from 54hpf with statin (mevastatin) or 
DMSO. Statin treatments induce a bar-like phenotype which is characterized by 
hemorrhages (asterisk) and heart failure (arrowhead). Scale bar, 300 m. (B) 3D 
projections of trunk vessels at 72hpf of DMSO and statin-treated zebrafish embryos. 
Statin treatments induce specific endothelial vessels regression and fragmentation in 
DA and Se (arrows). Scale bar, 100 m. (C) Quantification of bar-like phenotype 
after statin treatments. MEV, mevastatin 500nM; SIM; simvastatin 500nM; MEN, 
mevinolin 500nM. Levels of CoQ10 (D) and cholesterol (E) detected by HPLC-UV 
analyses in statin-treated embryos. Bright-field (F) and fluorescent (G) images of 
Tg(kdrl:GFP)s843 ubiad1+/+ and ubiad1+/- embryos at 65hpf treated with mevastatin 
(2.5nM and 5nM) from 32 to 50hpf. Treatment with low dose of statin caused 
hemorrhages (asterisks) and altered heart morphology (arrowheads) in ubiad1+/- but 
not in ubiad1+/+ embryos. Although treatment with low dose of statin did not induce 
specific alterations of the main vasculature, ubiad1+/- embryos showed head 
vasculature, Se and DA regression; scale bar: 300m. (H) Images of Tg(kdrl:GFP)s843 
ubiad1+/+ and ubiad1+/- embryos trunk vasculature show thinner and collapsed Se and 
DA morphology in statin-treated ubiad1+/- but not in ubiad1+/+ embryos. Scale bar: 
75m. (I) Penetrance of bar-like phenotype at 65hpf , after treatment with mevastatin. 
ubiad1+/- embryos are significantly more sensitive to develop a bar-like phenotype 
than normal embryos (ubiad1+/+). (J) CoQ10 supplemented embryos show less 
susceptibility to statin treatments in terms of developing a bar-like phenotype as 
indicated by histograms showing the percentage of statin-treated embryos having bar-
like phenotype after exogenous CoQ10 delivery. (K) CoQ10 supplementation before 
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statin treatment prevents cardiac edema (arrowhead) and brain hemorrhages (asterisk) 
in barolo. Images of vehicle- and CoQ10-injected embryos after statin treatment. 
Scale bar, 300m. (L) Histograms show oxidative stress in embryos after statin 
treatment with or without CoQ10.  
All data are means ± SEM ***p<0,001. 
See also Figure S3. 
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Figure 4: UBIAD1 is a prenyltransferase responsible for CoQ10 synthesis in the 
Golgi compartment. 
(A-B) Confocal images of human ECs showing Ubiad1 colocalization with Golgi 
markers. (A) DNA (blue), human Ubiad1(red), and TGN46 (green). (B) DNA (blue), 
zebrafish Ubiad1-GFP (green), GM130 (red). Scale bar, 20m. (C) High 
magnification confocal images of Golgi compartment showing colocalization between 
Ubiad1-GFP (green) and the Golgi marker -adaptin (red). Scale bar, 10m. (D) 
Fluorescence images of human ECs transfected with Ubiad1-GFP and treated or not 
with brefeldin A (+BFA). After BFA treatment, Ubiad1 localization becomes diffuse 
throughout the cell. Scale bar, 10m. (E) Golgi compartment (Golgi, ER and 
endosome fractions) and mitochondrial fractions from human ECs were analyzed by 
western blot with the following antibodies: Adaptin and Rab11, as marker for 
Golgi/ER/endosome fractions, HADHA (Hydroxyacyl-CoA Dehydrogenase/3-
ketoacyl-CoA thiolase/enoyl-CoA Hydratase (trifunctional protein), Alpha subunit) as 
marker for mitochondrial fractions. (F) Levels of 13C6-isotope labeled CoQ10 
(CoQ10-13C6) detected by HPLC-MS. Compared to control (siCTRL) the level of 
CoQ10-13C6 present in cells silenced for UBIAD1 (siUBIAD1) is significantly 
reduced in Golgi compartment but not in mitochondria. Data are means ± SD 
**p<0.01. 
See also Figure S4. 
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Figure 5: SCCD UBIAD1 variants rescue barolo mutants and positively regulate 
CoQ10 synthesis. 
A) wild-type UBIAD1 (WT) or SCCD UBIAD1 isoforms (N102S; D112G) rescue 
bar mutants at a significant extent. (B) Western blot analysis of protein extracts from 
HUAEC transfected with plasmids encoding for wild-type UBIAD1 (WT) or SCCD 
UBIAD1 isoforms (N102S; D112G). (C-E) HUAEC were transfected with plasmids 
encoding for wild-type UBIAD1 (WT) or SCCD UBIAD1 isoforms (N102S; D112G) 
and total lipid extracts were quantitated for CoQ10-13C6 (C ) and CoQ10 by HPLC-
MS (D) and for cholesterol by HPLC-UV (E). Expression of all UBIAD1 proteins 
rises levels of CoQ10 as well as de novo synthetized CoQ10-13C but does not change 
cholesterol levels in human ECs. 
All data are means ± SEM **p<0.01, ***p<0.001. 
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Figure 6: Ubiad1 and Coq2 play different functions during development.  
(A) Se integrity is affected in Tg(kdrl:GFP)s843 embryos injected with ubiad1 
morpholino (ubiad1 MO) but not in coq2 morphants (coq2 MO). Scale bar, 100 m. 
(B) Oxidative stress levels in entire ubiad1 morphants (ubiad1 MO), coq2 morphants 
(coq2 MO), and relative control (ctrl MO). (C) CoQ10 levels detected by HPLC-MS 
are significantly lower in ubiad1 morphants (ubiad1 MO), coq2 morphants (coq2 
MO), ubiad1 and coq2 double morphants (ubiad1+ coq2 MO) than control morphants 
(ctrl MO). (D). Embryos from bar heterozygote intercrosses were injected with coq2 
mRNA and mitochondria-targeted CoQ10 analog called MitoQ (10M) or cherry 
mRNA and Decyl-TPP (10M) as respective controls. Phenotypes were scored at 
72hpf. bar phenotype is not caused by lack of mitochondria CoQ10. (E) Silecing of 
both CoQ10 biosynthetic enzymes (siUBIAD1 and siCOQ2) cause increase of total 
cellular ROS in ECs. (F) Levels of CoQ10 detected by HPLC-MS in total lipid 
extracts from HUAEC silenced for UBIAD1 (siUBIAD1), COQ2 (siCOQ2) or both 
(siUBIAD1+siCOQ2). UBIAD1 and COQ2 were silenced with 50pmoles (black bars) 
or with 100pmoles (gray bars). Levels of CoQ10 are significantly reduced in cells 
silenced for UBIAD1 or COQ2 expression. (G) Quantitative PCR analyses of 
UBIAD1 and COQ2 mRNA levels in HUAEC cells. (H) Quantification of loss of 
mitochondrial membrane potential (Δψm) in HUAEC silenced for UBIAD1 
(siUBIAD1) or COQ2 (siCOQ2). (I) Quantification of lipid peroxidation by MDA 
adducts levels in HUAEC silenced for UBIAD1 (siUBIAD1) or COQ2(siCOQ2).  
All data are means ± SD **p<0,01, ***p<0,001.  
See also Figure S5. 
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Figure 7: NOS activity in cardiovascular tissues is regulated by UBIAD1 and CoQ10. 
(A) Knock-down of endothelial nitric oxide synthase 1 by morpholino (nos1 MO) 
reduces the penetrance of bar phenotype at 72 hpf. (B) Knock down of nos1 rescue 
endothelial integrity defects of bar mutants. Images of Se of bar  at 72hpf injected 
with nos1 morpholino (bar + nos1MO) or control morpholino (bar + ctrl MO)  Scale 
bar, 50m. (C) Bright-field images (left) and fluorescent micrographs showing the 
trunk vasculature (right) of Tg(kdrl:GFP)s843 bar treated from 48hpf with the specific 
eNOS inhibitor L-NAME (500). Heart failure (arrowhead) and endothelial 
regression (arrows) were fully rescued by L-NAME treatment. Scale bar, 100m. (D) 
Penetrance of the bar phenotype at 65hpf is significantly decreased by inhibition of 
eNOS activity with L-NAME treatment from 32hpf. (E) Oxidative stress level in ECs 
derived from Tg(kdrl:GFP)s843 bar mutant embryos is decreased by L-NAME 
treatment. (F) eNOS inhibition by L-NAME treatment significantly reduces ECs 
positive for S-Nitroso-cysteine (SNO-Cys) in DA and PCV of bar embryos. (G) 
Silencing of eNOS (sieNOS) rescues oxidative stress induced by the lack of UBIAD1 
(siUBIAD1). Silencing eNOS alone did not decrease ROS level in ECs. (H) Silencing 
of UBIAD1 gene (siUBIAD1) causes a significant decrease of eNOS activity in ECs 
evaluated as [3H]-L-citrulline. (I) Schematic representation of Ubiad1 molecular 
function in CoQ10 production and maintenance of nitrix oxide (NO) signalling. In 
wild-type cells, Ubiad1 localizes in the Golgi compartment and produces 
CoenzymeQ10 (CoQ10), an antioxidant molecule, important to counteract oxidative 
damage in particular in cellular membranes (cytosol and plasma membrane). In the 
Golgi compartment CoQ10 as an electron carrier might also play a fundamental role 
as a cofactor for eNOS activity by maintaining its “coupled” conformation and 
allowing normal NO production. On the other hand, lack of UBIAD1 and lowering of 
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CoQ10, as occurs in the cardiovascular tissues of bar mutants, might “uncouple” 
eNOS causing loss of NO production and consequently reactive oxygen species 
overload leading to cellular oxidative damage (e.g. lipid peroxidation). Thereby, the 
“barolo” phenotypes can be rescued by impairment of eNOS activity or expression.  
Data are means ± SEM *p<0.05**p<0,01***p<0,001. 
See also Figure S6. 
 
 
